NYSEAMERICAN:AZTR Azitra (AZTR) Stock Price, News & Analysis $0.60 0.00 (0.00%) (As of 09/19/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesInsider TradesOwnershipShort Interest Get Azitra alerts: Email Address About Azitra Stock (NYSEAMERICAN:AZTR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Azitra alerts:Sign Up Key Stats Today's Range$0.57▼$0.6450-Day Range N/A52-Week Range$0.49▼$68.40Volume403,804 shsAverage Volume1.04 million shsMarket Capitalization$4.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAzitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.Read More… Imminent FDA Decision Could End Obesity in America... (Ad)This drug could end obesity in America... ...and spark a 224,000% sales surge for one tiny micro-cap stock. Channelnomics says it "Could have a greater impact on the world than artificial intelligence."Get the name of this stock here >>> Azitra Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 20th PercentileAzitra scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Azitra.Read more about Azitra's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Azitra are expected to grow in the coming year, from ($3.06) to ($0.95) per share.Price to Book Value per Share RatioAzitra has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.81% of the float of Azitra has been sold short.Short Interest Ratio / Days to CoverAzitra has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Azitra has recently decreased by 24.74%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAzitra does not currently pay a dividend.Dividend GrowthAzitra does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.81% of the float of Azitra has been sold short.Short Interest Ratio / Days to CoverAzitra has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Azitra has recently decreased by 24.74%, indicating that investor sentiment is improving significantly. News and Social Media1.0 / 5News Sentiment-0.20 News SentimentAzitra has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Azitra this week, compared to 0 articles on an average week.Search InterestOnly 4 people have searched for AZTR on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Azitra to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Azitra insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.90% of the stock of Azitra is held by insiders.Percentage Held by InstitutionsOnly 11.16% of the stock of Azitra is held by institutions.Read more about Azitra's insider trading history. Receive AZTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Azitra and its competitors with MarketBeat's FREE daily newsletter. Email Address AZTR Stock News HeadlinesAzitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR InhibitorsSeptember 18 at 12:55 PM | finance.yahoo.comAzitra's ATR-04 Gets FDA Fast Track Designation For Skin Rash Linked To EGFR InhibitorsSeptember 18 at 12:55 PM | markets.businessinsider.com“I’ll Give You the Knowledge and Confidence You Need to Make Your First Options Trade in Five Days or Less… Guaranteed!”Starting Monday, September 23 — a veteran 25-year Chicago Options Exchange market-maker will show you his UOA options secret that could help you consistently target gains of 126%… 245%… even 463% or more… Often in 30 days or less… No matter what the market is doing right now.September 19, 2024 | InvestorPlace (Ad)Azitra to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 7, 2024 | finance.yahoo.comAzitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton SyndromeAugust 28, 2024 | finance.yahoo.comAzitra Inc (AZTR) Receives a Buy from Maxim GroupAugust 28, 2024 | markets.businessinsider.comAZTR: First ATR-12 Patient ScreenedAugust 24, 2024 | finance.yahoo.comAzitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR InhibitorsAugust 23, 2024 | finance.yahoo.comSee More Headlines AZTR Stock Analysis - Frequently Asked Questions How have AZTR shares performed this year? Azitra's stock was trading at $2.7660 at the start of the year. Since then, AZTR stock has decreased by 78.3% and is now trading at $0.5990. View the best growth stocks for 2024 here. How were Azitra's earnings last quarter? Azitra, Inc. (NYSEAMERICAN:AZTR) released its earnings results on Monday, August, 12th. The company reported ($2.74) earnings per share for the quarter, missing the consensus estimate of ($2.59) by $0.15. The company earned $0.01 million during the quarter. Azitra had a negative trailing twelve-month return on equity of 278.76% and a negative net margin of 1,644.90%. When did Azitra's stock split? Azitra's stock reverse split on the morning of Monday, July 1st 2024. The 1-30 reverse split was announced on Monday, July 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Azitra? Shares of AZTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/12/2024Today9/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:AZTR CUSIPN/A CIKN/A Webazitrainc.com Phone203-646-6446FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,280,000.00 Net Margins-1,644.90% Pretax Margin-2,435.53% Return on Equity-278.76% Return on Assets-176.66% Debt Debt-to-Equity Ratio0.01 Current Ratio0.77 Quick Ratio0.77 Sales & Book Value Annual Sales$690,000.00 Price / Sales6.66 Cash FlowN/A Price / Cash FlowN/A Book Value$7.23 per share Price / Book0.08Miscellaneous Outstanding Shares7,630,000Free Float912,000Market Cap$4.59 million OptionableNot Optionable Beta-1.84 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NYSEAMERICAN:AZTR) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredForget ChatGPT: Follow the AI Retirement PlaybookEveryone’s talking about AI right now, but I’ve been talking about it for years. Follow this two-part playb...Brownstone Research | SponsoredDump Nvidia, Apple, and Tesla Before It’s Too LateThe financial world is on high alert. Billionaires like Warren Buffett, Jeff Bezos, and Elon Musk are dumpi...InvestorPlace | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Azitra, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Azitra With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.